[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Alfredo M [@AlfredoM617](/creator/twitter/AlfredoM617) on x XXX followers Created: 2025-07-14 19:36:07 UTC Viking $VKTX Is Not Just “Another GLP-1 Play” Viking Therapeutics is one of the most underappreciated pipeline stories in biotech. It has: A dual-form GLP-1/GIP agonist that may be best-in-class A NASH drug with market-leading data and lipid benefits A rare disease candidate that could be first-in-class $1B in cash, allowing it to go to market alone or with leverage Strong clinical and mechanistic de-risking Multiple paths to monetization, including partnership or M&A In short, Viking could evolve from a clinical-stage innovator to a dominant metabolic franchise, or become the most lucrative buyout in biotech this cycle. With key Phase X readouts coming and competitive scarcity increasing, the stock’s current price may soon look like a historical anomaly. XXXXX engagements  **Related Topics** [1b](/topic/1b) [$1b](/topic/$1b) [$vik](/topic/$vik) [$vktx](/topic/$vktx) [Post Link](https://x.com/AlfredoM617/status/1944843369181561151)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Alfredo M @AlfredoM617 on x XXX followers
Created: 2025-07-14 19:36:07 UTC
Viking $VKTX Is Not Just “Another GLP-1 Play”
Viking Therapeutics is one of the most underappreciated pipeline stories in biotech. It has:
A dual-form GLP-1/GIP agonist that may be best-in-class
A NASH drug with market-leading data and lipid benefits
A rare disease candidate that could be first-in-class
$1B in cash, allowing it to go to market alone or with leverage
Strong clinical and mechanistic de-risking
Multiple paths to monetization, including partnership or M&A
In short, Viking could evolve from a clinical-stage innovator to a dominant metabolic franchise, or become the most lucrative buyout in biotech this cycle. With key Phase X readouts coming and competitive scarcity increasing, the stock’s current price may soon look like a historical anomaly.
XXXXX engagements
/post/tweet::1944843369181561151